Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Jan;29(1):182–183. doi: 10.1128/aac.29.1.182

In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier.

E Palenque, J R Otero, A R Noriega
PMCID: PMC180392  PMID: 3729331

Abstract

The in vitro susceptibilities of 83 clinical isolates of Brucella melitensis to seven cephalosporins and a monobactam were determined. Ceftizoxime, ceftriaxone, and cefotaxime were the most effective agents tested, with MICs ranging from 0.25 to 2 micrograms/ml. Moxalactam, cefoperazone, cefuroxime, and ceftazidime showed MICs between 4 and 64 micrograms/ml, with moxalactam being the most active agent in this group. Aztreonam showed poor activity, with MICs higher than 64 micrograms/ml.

Full text

PDF
182

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Congeni B. L. Comparison of ceftriaxone and traditional therapy of bacterial meningitis. Antimicrob Agents Chemother. 1984 Jan;25(1):40–44. doi: 10.1128/aac.25.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Corbel M. J. Determination of the in vitro sensitivity of Brucella strains to rifampicin. Br Vet J. 1976 May-Jun;132(3):266–275. doi: 10.1016/s0007-1935(17)34686-9. [DOI] [PubMed] [Google Scholar]
  3. FINCHAM R. W., SAHS A. L., JOYNT R. J. Protean manifestations of nervous system brucellosis. Case histories of a wide variety of clinical forms. JAMA. 1963 Apr 27;184:269–275. doi: 10.1001/jama.1963.03700170061009. [DOI] [PubMed] [Google Scholar]
  4. Gutiérrez Altés A., Díez Enciso M., Peña García P., Campos Bueno A. In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole. Antimicrob Agents Chemother. 1982 Mar;21(3):501–503. doi: 10.1128/aac.21.3.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hall W. H., Manion R. E. In vitro susceptibility of Brucella to various antibiotics. Appl Microbiol. 1970 Oct;20(4):600–604. doi: 10.1128/am.20.4.600-604.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Neu H. C. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982 Sep;97(3):408–419. doi: 10.7326/0003-4819-97-3-408. [DOI] [PubMed] [Google Scholar]
  7. Overturf G. D., Cable D. C., Forthal D. N., Shikuma C. Treatment of bacterial meningitis with ceftizoxime. Antimicrob Agents Chemother. 1984 Feb;25(2):258–262. doi: 10.1128/aac.25.2.258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Patel I. H., Kaplan S. A. Pharmacokinetic profile of ceftriaxone in man. Am J Med. 1984 Oct 19;77(4C):17–25. [PubMed] [Google Scholar]
  9. Sande M. A. Antibiotic therapy of bacterial meningitis: lessons we've learned. Am J Med. 1981 Oct;71(4):507–510. doi: 10.1016/0002-9343(81)90191-1. [DOI] [PubMed] [Google Scholar]
  10. Young E. J. Human brucellosis. Rev Infect Dis. 1983 Sep-Oct;5(5):821–842. doi: 10.1093/clinids/5.5.821. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES